1 / 14

PROCABIO A European initiative to develop tailored treatment of prostate cancer by biomarkers

PROCABIO A European initiative to develop tailored treatment of prostate cancer by biomarkers. Objectives PROCABIO (Tailored treatment of pro state ca ncer by bio markers). Integration biomarkers in updated and improved model for indolent prostate cancer

caleb-fleming
Download Presentation

PROCABIO A European initiative to develop tailored treatment of prostate cancer by biomarkers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROCABIOA European initiative to developtailored treatment of prostate cancerby biomarkers

  2. Objectives PROCABIO(Tailored treatment of prostate cancer by biomarkers) • Integration biomarkers in updated and improved model for indolent prostate cancer • Integration biomarkers in development of guidelines for efficient strategies for active surveillance • Delivery validated biomarker tools that are easily applicable for high throughput use in clinical and screening settings • Establishment overall acceptance of active surveillance as a treatment modality for indolent prostate cancer For more information, contact e.schenk-braat@erasmusmc.nl

  3. PROCABIO consortium (18 partners) 11 clinical & academic partners5 commercial partners Erasmus MC (NL) Abacus Diagnostica (FIN) Institute of Cancer Research (UK) Beckman-Coulter (FR) L’Hôpital Saint-Louis (FR) Epigenomics (GE) Lund University (SE) Gen-Probe Incorporated (USA) Milan National Cancer Institute (I) Orion Diagnostica Oy (FIN) RUNMC (NL) University of Helsinki (FIN) 2 advisory partners University of Münster (GE) EORTC (BE) University of Sheffield (UK) Europa Uomo (BE) University of Tampere (FIN) University of Turku (FIN) For more information, contact e.schenk-braat@erasmusmc.nl

  4. Biomarker implementation in treatment policies Guidelines on active surveillance PROCABIO plan for 3 years Central biorepository of blood and urine Active surveillance trial in 8 centers according to PRIAS protocol with 3 years follow-up Validation in blood, urine or tissue of proteomic and genomic biomarkers discriminating indolent and progressive PCa Informing stakeholders on progress and outcome active surveillance study & biomarker implementation For more information, contact e.schenk-braat@erasmusmc.nl

  5. Europe as a scaffold to integrate research for prostate cancer patients PCa patients involvement (Europa Uomo) Clinical Centres implementation targeted treatment Marker industries Academic Research • Abacus • Beckman Coulter • Epigenomics • Gen-Probe • Orion • Malmö • Nijmegen • Munster • Rotterdam • Sheffield • Turku • Helsinki • Finland • France • Germany • Netherlands • Sweden • UK • Belgium • Italy • Lithuania Archival Biomaterials (via P-Mark, ERSPC, ProtecT) Genomic, proteomic, molecular pathology Biomarkers Prospective Biomaterials (via PRIAS-study) Marker based guidelines for PCa patients (EORTC, EAU)

  6. PROCABIO contact details PROCABIO coordinatorPROCABIO project manager Prof. dr. Chris Bangma Dr. Ellen Schenk-Braat Erasmus MC Erasmus MC Department of Urology Department of Urology Room H1096 JNI, room Be362 T. +31-10-7033607 T. +31-10-7043674 F. +31-10-7035838 F. +31-10-7044661 h.j.vanalphen@erasmusmc.nl e.schenk-braat@erasmusmc.nl

  7. Erasmus MC Department of Urology PI Prof. dr. Chris Bangma 50 patients

  8. University Hospital Malmö Department of Urology PI Prof. dr. Anders Bjartell 25 patients

  9. Institute of Cancer Research, London PI Dr. Chris Parker 100 patients

  10. Tampere University Hospital Department of Urology PI Prof. dr. Teuvo Tammela 80-100 patients

  11. Milan National Cancer Institute PI Prof. dr. Riccardo Valdagni 40 patients

  12. EAU Best paper 2007 by a resident

  13. 2006 2002 …early detection… Prostate Cancer International study of Active Surveillance 2007 2008 Biomarker research PROCABIO Prostate Cancer Biomarker research in clinical setting of Active Surveillance 2008 Prostate Cancer Risk Calculator 2007 Patient organisations Health care professionals Integrating Europe for Prostate Cancer

More Related